Images List Premium Download Classic

Monoclonal

Monoclonal-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Antibodies against the rgm a protein and uses thereof
Abbvie Inc.
June 15, 2017 - N°20170166633

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize rgm a protein. Specifically, these antibodies have the ability to inhibit the binding of rgm a to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting rgm a and for inhibiting rgm a activity, for example in a ...
Humanized anti-factor d antibodies and uses thereof
Genentech, Inc.
June 15, 2017 - N°20170166630

The invention relates to humanized anti-human factor d monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
Immunoglobulins and variants directed against pathogenic microbes
Genentech, Inc.
June 15, 2017 - N°20170166629

Anti-microbial monoclonal antibodies and variant antibodies having a heavy chain constant regions with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections.
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
A new biomarker of chronic allograft nephropathy and of renal transplant rejection
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
June 08, 2017 - N°20170160290

The invention relates to a method for determining whether a renal transplanted patient is at risk of transplant rejection or can, comprising a step of determining the expression level of the periostin (postn) gene on a renal transplant biopsy obtained from said transplanted patient. The invention also relates to a compound selected from the group consisting of monoclonal anti-cd20 antibodies, ...
Compositions and methods for targeting of the surfactant protein a receptor
The Penn State Research Foundation
June 08, 2017 - N°20170158768

Provided are compositions and methods for use in prophylaxis, therapy and diagnosis of conditions which involve surfactant protein receptors (spr) including the spr for surfactant proteins a (spa). Specific binding partners, including mono-clonal antibodies, for the sp-r210l and sp-r210s isoforms, and methods of using such binding partners are included. Fragments of the monoclonal antibodies, and fusion proteins that ...
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
E.r. Squibb & Sons, L. L. C.
June 08, 2017 - N°20170158767

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The ...
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a ...
Celltrion, Inc.
June 08, 2017 - N°20170158754

The present invention relates to human monoclonal antibodies derived from human b cells present in the blood of patients who had recovered from infection with influenza a viruses, wherein the monoclonal antibodies have neutralizing activity against influenza a viruses. The anti-influenza a virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza a ...
Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
Integrated Biotherapeutics, Inc.
June 08, 2017 - N°20170158753

The disclosure provides binding molecules, e. G., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.
Lectin-like oxidized ldl receptor 1 antibodies and methods of use
Novartis Ag
June 01, 2017 - N°20170152313

The present invention relates to monoclonal antibodies binding to human lectin-like oxidized ldl (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “lox-1”), and pharmaceutical compositions and methods of treatment comprising the same.
M-csf specific monoclonal antibody and uses thereof
Xoma Technology Ltd.
June 01, 2017 - N°20170152311

M-csf-specific rx1-based or rx-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
Antibodies recognizing alpha-synuclein
Prothena Biosciences Limited
June 01, 2017 - N°20170152310

The invention provides monoclonal antibody 5c1 and related antibodies. The 5c1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include lewy body diseases, such as parkinson's disease, ...
Single chain variable fragment (scfv) elongation mutants
Universitat Autonoma De Barcelona
June 01, 2017 - N°20170152306

The present invention relates to the provision of single chain variable fragment (scfv) elongation mutants. In addition, the present invention relates to a pharmaceutical composition comprising said scfv elongation mutants, as well as a nucleotide sequence encoding said scfv elongation mutants, a vector comprising said nucleotide sequence or a host cell expressing said nucleotide sequence. Particular embodiments relate to elongation ...
Methods for increasing the diversity of monoclonal antibodies produced against an antigen
Universitat Autonoma De Barcelona
May 25, 2017 - N°20170145407

The present invention relates to methods for increasing the diversity of monoclonal antibodies produced against an antigen. The methods of the invention utilize immunization of a murine host defective in one or more enzymes involved in a post-translational modification of a polypeptide or a modification of a lipid, wherein said modification is exposed on a cell surface. The invention also ...
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Chimeric antigen receptor hcd87-car and applications thereof
Universitat Autonoma De Barcelona
May 25, 2017 - N°20170145106

The present invention relates to a cellular immunotherapy for treatment of tumors, particularly to a peptide of a chimeric antigen receptor hcd87-car and the applications thereof, the peptide of said antigen receptor being carried by a vector packaged in a lentivirus. The chimeric antigen receptor hcd87-car contains a fragment of anti cd87 monoclonal antibody hcd87scfv consisting of ...
Human monoclonal antibodies specific for cd22
Universitat Autonoma De Barcelona
May 25, 2017 - N°20170145097

Disclosed herein are isolated human monoclonal antibodies that specifically bind human cd22 with a dissociation constant (kd) of 25 nm or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human cd22 in a sample. In some ...
Cd33 specific chimeric antigen receptors for cancer immunotherapy
Universitat Autonoma De Barcelona
May 25, 2017 - N°20170145094

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a cd33 monoclonal antibody, conferring specific immunity against cd33 positive cells. The engineered immune cells endowed with such cars are particularly ...
Pharmaceutical compositions with resistance to soluble cea
Amgen Research (munich) Gmbh
May 18, 2017 - N°20170137538

The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human cd3, and a second binding domain specifically binding to human cea, where the second binding domain comprises at least a part of the cdr-h3 or the complete cdr-h3 of murine monoclonal antibody a5b7, a pharmaceutical composition comprising the bispecific ...
Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
Csl Ltd.
May 18, 2017 - N°20170137536

The invention relates to inhibitory anti-factor xii/fxiia antibodies and methods of their use.
Anti-factor d antibody formulations
Genentech, Inc.
May 18, 2017 - N°20170137535

Pharmaceutical formulations comprising monoclonal anti-factor d antibodies, and their production and use for the treatment of complement-associated ocular diseases are disclosed. The formulations include pre-lyophilized, lyophilized and reconstituted stable liquid formulations of anti-factor d antibodies, including lampalizumab.
Use of interleukin-4 antagonists and compositions thereof
Immunex Corporation
May 18, 2017 - N°20170137526

Methods for treating medical conditions induced by interleukin-4 involve administering an il-4 antagonist to a patient afflicted with such a condition. Suitable il-4 antagonists include, but are not limited to, il-4 receptors (such as a soluble human il-4 receptor), antibodies that bind il-4, antibodies that bind il-4r, il-4 muteins that bind to il-4r but do not induce a ...
Targeted binding agents against b7-h1
Medimmune Limited
May 18, 2017 - N°20170137522

Human monoclonal antibodies directed against b7-h1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of b7-h1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
Loading